Pravin Dugel - 24 Aug 2026 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Reporting relationship: Executive Chairman, President and CEO, Director
Issuer ticker: OCUL
Reported as of: 24 Aug 2026
Net transaction value: -$233,160
SEC form: 4
Accepted by SEC: 26 Aug 2026, 17:56:14 UTC
Prior SEC filing: 18 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Todd Anderman, Attorney-in-Fact for Pravin Dugel

Key filing fact

Pravin Dugel filed Form 4 for OCULAR THERAPEUTIX, INC (OCUL) on 26 Aug 2026.

Key facts

This page summarizes Pravin Dugel's Form 4 filing for OCULAR THERAPEUTIX, INC (OCUL).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 26 Aug 2026, 17:56.

Change

Previous filing in this sequence was filed on 18 Jun 2026.
Current net transaction value: -$233,160.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001700917 Primary reporting owner

Dugel Pravin

Relationship: Executive Chairman, President and CEO, Director
Address: C/O OCULAR THERAPEUTIX, INC., 14 CROSBY DRIVE, 3RD FLOOR, BEDFORD
Signature: /s/ Todd Anderman, Attorney-in-Fact for Pravin Dugel
Signature date: 26 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

OCUL transaction

Common Stock

Sale

Transaction value: $233,160
Shares: -21,649
Change %: -0.85%
Price: $10.77
Shares after: 2,525,429
Date: 24 Aug 2026
Ownership: Direct
Footnotes: F1, F2

OCUL transaction

Common Stock

Gift

Transaction value
Shares: -50,092
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 25 Aug 2026
Ownership: By spouse
Footnotes: F3

OCUL transaction

Common Stock

Gift

Transaction value
Shares: +50,092
Change %: +7.2%
Price: $0.000000^*
Shares after: 744,903
Date: 25 Aug 2026
Ownership: By Pravin Dugel 2024 Irrevocable Trust
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on February 21, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on August 22, 2026. The sales do not represent a discretionary trade by the reporting person.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.6400 to $10.9000, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Footnote F3

On August 25, 2026, the reporting person's spouse transferred 50,092 shares to the Pravin Dugel 2024 Irrevocable Trust (the "Trust") for no consideration. The reporting person is trustee of the Trust and sole beneficiary of the Trust during his lifetime. The reporting person remains the beneficial owner of the securities held by the Trust.

SEC remarks

Executive Chairman, President and CEO